GlassScriptPhysician profile
Raymond W Workman
NPI 1649275512
$5,096.46
in general payments reported to CMS, 2019-2025
29 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,113 · 2020: $1,068 · 2021: $1,241 · 2022: $855 · 2023: $398 · 2024: $205 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,146.91 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $400.04 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.33 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $384.87 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $368.40 | 2019-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $322.03 | 2019-2024 | Uptravi |
| Biotronik INC. | $246.88 | 2019-2020 | |
| Pfizer INC. | $239.78 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $192.34 | 2019-2023 | Livalo |
| Akcea Therapeutics, INC. | $183.31 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $147.29 | 2022-2025 | Verquvo |
| Abbott Laboratories | $140.07 | 2019-2023 | Jot Dx |
| Astrazeneca Pharmaceuticals LP | $123.33 | 2019-2024 | Farxiga |
| Cook Medical LLC | $102.98 | 2022 | |
| Amgen INC. | $88.92 | 2019-2023 | Repatha |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $88.57 | 2025 | Wegovy |
| Astellas Pharma US INC | $75.96 | 2019-2022 | |
| Boston Scientific Corporation | $68.01 | 2019-2021 | |
| Cardiva Medical, INC. | $67.98 | 2019-2024 | Cardiva Vascade 5f Vcs |
| Alnylam Pharmaceuticals INC. | $67.08 | 2019-2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $47.91 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.37 | 2022 | |
| Sobi, INC | $45.73 | 2021-2022 | |
| Medtronic, INC. | $39.19 | 2021 | |
| Scpharmaceuticals INC. | $17.79 | 2025 | |
| Amarin Pharma, INC. | $16.63 | 2019 | |
| Ge Healthcare | $13.81 | 2025 | |
| Medicomp INC | $13.77 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.